Efficacy, Safety and Immunogenicity in Randomized, Double-Blind (DB) and OpenLabel Extension (OLE) Studies Comparing FKB327, an Adalimumab Biosimilar, with the Adalimumab Reference Product (Humira®; RP) in Patients (pts) with Active Rheumatoid Arthritis (RA)

被引：0
|
作者：
Genovese, Mark C. [1 ]
Glover, Josephine [2 ]
Matsunaga, Nobuhito [3 ]
Chisholm, Diane [4 ]
Alten, Rieke [5 ]
机构：
[1] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA
[2] Coephycient Pharmaceut Consultancy, Guildford, Surrey, England
[3] Fujifilm Kyowa Kirin Biol, Chiyoda Ku, Tokyo, Japan
[4] Fujifilm Kyowa Kirin Biol, Galashiels, Scotland
[5] Univ Med Berlin, Berlin, Germany
来源：
ARTHRITIS & RHEUMATOLOGY | 2017年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2799
引用
收藏
页数：2
相关论文
共 50 条
  • [11] A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis
    Ahmadreza Jamshidi
    Farhad Gharibdoost
    Mahdi Vojdanian
    Soosan G. Soroosh
    Mohsen Soroush
    Arman Ahmadzadeh
    Mohammad Ali Nazarinia
    Mohammad Mousavi
    Hadi Karimzadeh
    Mohammad Reza Shakibi
    Zahra Rezaieyazdi
    Maryam Sahebari
    Asghar Hajiabbasi
    Ali Asghar Ebrahimi
    Najmeh Mahjourian
    Amin Mohammadinejad Rashti
    Arthritis Research & Therapy, 19
  • [12] A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis
    Jamshidi, Ahmadreza
    Gharibdoost, Farhad
    Vojdanian, Mahdi
    Soroosh, Soosan G.
    Soroush, Mohsen
    Ahmadzadeh, Arman
    Nazarinia, Mohammad Ali
    Mousavi, Mohammad
    Karimzadeh, Hadi
    Shakibi, Mohammad Reza
    Rezaieyazdi, Zahra
    Sahebari, Maryam
    Hajiabbasi, Asghar
    Ebrahimi, Ali Asghar
    Mahjourian, Najmeh
    Rashti, Amin Mohammadinejad
    ARTHRITIS RESEARCH & THERAPY, 2017, 19
  • [13] Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
    Roy M. Fleischmann
    Daniel F. Alvarez
    Amy E. Bock
    Carol Cronenberger
    Ivana Vranic
    Wuyan Zhang
    Rieke Alten
    Arthritis Research & Therapy, 23
  • [14] A Phase III, Randomized, Double-Blind Clinical Study Comparing SB5, an Adalimumab Biosimilar, with Adalimumab Reference Product (Humira®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (24-week Results)
    Weinblatt, Michael E.
    Baranauskaite, Asta
    Niebrzydowski, Jaroslaw
    Dokoupilova, Eva
    Zielinska, Agnieszka
    Sitek-Ziolkowska, Karina
    Jaworski, Janusz
    Racewicz, Artur
    Pileckyte, Margarita
    Jedrychowicz-Rosiak, Krystyna
    Zhdan, Vyacheslav
    Cheong, Soo Yeon
    Ghil, Jeehoon
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [15] Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trial
    Fleischmann, Roy M.
    Alvarez, Daniel F.
    Bock, Amy E.
    Cronenberger, Carol
    Vranic, Ivana
    Zhang, Wuyan
    Alten, Rieke
    ARTHRITIS RESEARCH & THERAPY, 2021, 23 (01)
  • [16] A Randomized, Double-blind Phase 3 Study Comparing the Efficacy, Safety and Immunogenicity of PF-06410293 (AbriladaT), an Adalimumab (ADL) Biosimilar, and Reference ADL (Humira®) in Patients with Moderate to Severe Active RA: Results from Weeks 52-92
    Fleischmann, Roy
    Alvarez, Daniel
    Bock, Amy
    Cronenberger, Carol
    Vranic, Ivana
    Zhang, Wuyan
    Alten, Rieke
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [17] SAFETY, IMMUNOGENICITY AND EFFICACY OF THE PROPOSED BIOSIMILAR MSB11022 (MODIFIED FORMULATION) COMPARED WITH ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS: AURIEL-RA, A RANDOMISED, DOUBLE-BLIND, PHASE III STUDY
    Edwards, Christopher
    Chyrok, Veronica
    Monnet, Joelle
    Ullmann, Martin
    Vlachos, Pantelis
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 707 - 707
  • [18] Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study
    Cohen, Stanley B.
    Alonso-Ruiz, Alberto
    Klimiuk, Piotr A.
    Lee, Eric C.
    Peter, Nuala
    Sonderegger, Ivo
    Assudani, Deepak
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (06) : 914 - 921
  • [19] Response to Jani et al. A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis
    Kane, Barry
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2017, 20 (11) : 1791 - 1791
  • [20] A randomized double-blind trial comparing the efficacy, safety, and immunogenicity of MSB11022, a proposed biosimilar of adalimumab, versus adalimumab originator in patients with moderate-to-severe plaque psoriasis
    Hercogova, Jana
    Papp, Kim A.
    Edwards, Christopher J.
    Chyrok, Veranika
    Halady, Tanuja
    Ullman, Martin
    Vlachos, Pantelis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB21 - AB21
12345